(Q36585434)

15 August 2017

Local therapy of cancer with free IL-2. (English)

1 reference

15 August 2017

Willem Den Otter

1

1 reference

15 August 2017

John J L Jacobs

2

1 reference

15 August 2017

Jan J Battermann

3

1 reference

15 August 2017

Gerrit Jan Hordijk

4

1 reference

15 August 2017

Zachary Krastev

5

1 reference

15 August 2017

Ekaterina V Moiseeva

6

1 reference

15 August 2017

Rachel J E Stewart

7

1 reference

15 August 2017

Paul G P M Ziekman

8

1 reference

15 August 2017

Jan Willem Koten

9

1 reference

15 August 2017

1 July 2008

1 reference

Cancer Immunology, Immunotherapy

15 August 2017

1 reference

15 August 2017

57

1 reference

15 August 2017

7

1 reference

15 August 2017

931-950

1 reference

Retrospective review in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2.

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Locoregional IL-2 low dose applications for gastrointestinal tumors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

IL-2, regulatory T cells, and tolerance

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

T cell anergy and costimulation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Testing therapeutic potency of anticancer drugs in animal studies: a commentary

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Interleukin-2 in the treatment of renal cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Analysis of T cell function in autoimmune murine strains. Defects in production and responsiveness to interleukin 2

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Interleukin-2 inhibits proliferation of HPV-associated tumor cells and halts tumor growth in vivo

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Tissue distribution and tumor localization of effector cells in adoptive immunotherapy of cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

A phase I study of intravesical continuous perfusion of recombinant interleukin-2 in patients with superficial bladder cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Effect of perilesional injections of PEG-interleukin-2 on basal cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Vascular leak syndrome: a side effect of immunotherapy

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with neoplastic pleural effusion.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Peri-tumor interleukin-2 causes systemic therapeutic effect via interferon-gamma induction

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Treatment of murine transitional cell carcinoma with intralesional interleukin 2 and murine interferon gamma

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Tumour regression by IL-2 mediated stagnation of blood flow

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Intracavitary administration of interleukin-2 as palliative therapy for neoplastic effusions

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Local interleukin-2 and interleukin-12 therapy of bovine ocular squamous cell carcinomas

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Interleukin-2, but not interleukin-15, is required to terminate experimentally induced clonal T-cell anergy

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Thymus requirement and antigen dependency in the "infectious" tolerance pathway in transplant recipients

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Interleukin-2: hope in cases of cisplatin-resistant tumours.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: six years of experience

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations. Preliminary report

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2335290

High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma

20 September 2018

1 reference

12 December 2020

Perilesional IL-2 treatment of a VX2 head-and-neck cancer model can induce a systemic anti-tumour activity

1 reference

12 December 2020

Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2

1 reference

12 December 2020

A mesothelioma that is sensitive to locally applied IL-2

1 reference

12 December 2020

The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy

1 reference

12 December 2020

Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2

1 reference

12 December 2020

Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer

1 reference

12 December 2020

Local interleukin-2 therapy in bovine ocular squamous cell carcinoma

1 reference

12 December 2020

Maintenance and cure of the L5178Y murine tumor-dormant state by interleukin 2: in vivo and in vitro effects

1 reference

12 December 2020

Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases

1 reference

12 December 2020

Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report

1 reference

12 December 2020

Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour

1 reference

12 December 2020

Intratumoral interleukin-2 immunotherapy: Activation of tumor-infiltrating and splenic lymphocytes in vivo

1 reference

12 December 2020

Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma

1 reference

12 December 2020

The immunobiological effects of interleukin-2 in vivo

1 reference

12 December 2020

Treatment of transitional cell carcinoma of the bladder with intravesical interleukin-2: a pilot study

1 reference

12 December 2020

Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up

1 reference

12 December 2020

Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2

1 reference

12 December 2020

Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13

1 reference

12 December 2020

Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2

1 reference

12 December 2020

Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2

1 reference

12 December 2020

Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study

1 reference

12 December 2020

Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2)

1 reference

12 December 2020

Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study

1 reference

12 December 2020

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion

1 reference

12 December 2020

The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration

1 reference

12 December 2020

Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients

1 reference

12 December 2020

Further development of local IL-2 therapy of cancer: multiple versus single IL-2 treatment of transplanted murine colon carcinoma

1 reference

12 December 2020

Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients

1 reference

12 December 2020

Microvascular pressures in DMBA-induced rat mammary tumours

1 reference

12 December 2020

Vascular Endothelium as the Vulnerable Element in Tumours

1 reference

12 December 2020

Tumour inhibitory effects of TCGF/IL-2/-containing preparations

1 reference

12 December 2020

Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice

1 reference

12 December 2020

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2

1 reference

12 December 2020

Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide

1 reference

12 December 2020

The anti-tumour efficacy of human recombinant interleukin 2. Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo

1 reference

12 December 2020

Local and systemic effects during interleukin-2 therapy of mouse mammary tumors

1 reference

12 December 2020

Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma

1 reference

12 December 2020

PEG-IL-2 therapy of advanced cancer in the guinea pig. Impact of the primary tumor and beneficial effect of cyclophosphamide

1 reference

12 December 2020

Re: Interleukin-2 in T1 papillary bladder carcinoma: regression of the marker lesion in 8 of 10 patients

1 reference

12 December 2020

Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2

1 reference

12 December 2020

Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength

1 reference

12 December 2020

Local low-dose IL-2 therapy

1 reference

12 December 2020

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study

1 reference

12 December 2020

Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth

1 reference

12 December 2020

Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour

1 reference

12 December 2020

Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells

1 reference

12 December 2020

Local interleukin 2 therapy is most effective against cancer when injected intratumourally

1 reference

12 December 2020

Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2

1 reference

12 December 2020

Changes in cytokine profile during local IL-2 therapy in cancer patients

1 reference

12 December 2020

Treatment of ocular squamous cell carcinomas in cattle with interleukin-2

1 reference

12 December 2020

10.1007/S00262-008-0455-Z

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

18256831

1 reference